RXRX
Recursion is a clinical-stage TechBio company developing small molecule drugs across multiple therapeutic areas using its Recursion Operating System, an AI-native platform that integrates biological data generation, AI-powered molecular synthesis, and AI-enabled clinical development. The company has demonstrated clinical validation with a positive readout in its familial adenomatous polyposis program using a MEK1/2 inhibitor, along with multiple clinical-stage and preclinical programs differentiated by novel biology and chemistry insights. Recursion has established strategic partnerships with companies including Roche, Genentech, and Sanofi, and has received over $500 million in partner payments for novel data generation and AI-designed small molecule program advancement.
Pipeline
Catalyst Calendar
“On September 3, 2024, the Company issued a press release announcing top-line results of its SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic cerebral cavernous malformation patients.”